No Abstract Assistant Managing EditorWith buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound.

No Abstract BioWorld International CorrespondentCevec Pharmaceuticals GmbH raised €4 million (US$5.9 million) in new funding to support the commercialization of its proprietary protein expression platform CAP, which the company is positioning as a high-yield technology for the production of complex proteins.